The aforementioned statement highlights the vital importance of TREM-1 in the inflammatory phase of colitis, indicating that inhibiting TREM-1 holds significant potential for alleviating visceral hyperalgesia in IBD. This evidence concerns the gene TREM1 and inflammatory bowel disease.